As of Nov 19, 2026, 2 of 2 active firms rate ACTU a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
ACTU EPS & revenue forecast
EPS · NEXT QUARTER
$-0.19
Range $-0.19 – $-0.19 · 1 analysts · -21% YoY
Next period, 1 analysts expect Actuate Therapeutics, Inc. Common stock to earn $-0.19 a share (range $-0.19 – $-0.19), versus $-0.24 a year earlier. Full-year consensus is $-0.54, growing to $-0.66 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 1 analysts · +0% YoY
Revenue is expected to reach $0 (range $0 – $0), +0.0% year-over-year. Full-year consensus is $0, rising to $0 next year.
Top analysts covering Actuate Therapeutics, Inc. Common stock
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ACTU.
#1
Mayank Mamtani
B. Riley Securities · Rank #36
Buy
$20.00+7775.6% to target
Overall win rate
49%
+ Follow
#2
Swayampakula Ramakanth
HC Wainwright & Co. · Rank #321
Buy
$15.00+5806.7% to target
Overall win rate
38%
+ Follow
#3
MK
Michael King
Rodman & Renshaw
Buy
$6.00+2262.7% to target
Coverage
—
+ Follow
#4
MG
Michael G. King Jr.
Rodman & Renshaw
Buy
$6.00+2262.7% to target
Coverage
—
+ Follow
#5
CL
Christopher Liu
Lucid Capital
Buy
$5.00+1868.9% to target
Coverage
—
+ Follow
ACTU stock forecast FAQ
What is ACTU's average 12-month price target?+
The 2 active firms with a live target average $10.50 for Actuate Therapeutics, Inc. Common stock over the next 12 months, ranging from a $15.00 high to a $6.00 low, as of Nov 19, 2026.
Is ACTU stock a Buy, Sell or Neutral right now?+
The current consensus is Insufficient coverage. Of the 2 active firms as of Nov 19, 2026, 2 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for ACTU?+
The Street-high target is $15.00 (HC Wainwright & Co.), and the Street-low is $6.00 (Rodman & Renshaw). The average of all 2 active-firm targets is $10.50.
How many active Wall Street firms cover ACTU?+
2 active firms have a recognized rating on Actuate Therapeutics, Inc. Common stock as of Nov 19, 2026, and 2 active firms carry a live 12-month price target.
Who is the most accurate analyst covering ACTU?+
Among analysts who currently cover ACTU, Mayank Mamtani of B. Riley Securities has the strongest overall Quantellect track record (Rank #36). Their current call is Buy with a $20.00 target.
What is Actuate Therapeutics, Inc. Common stock's projected EPS for next quarter?+
The consensus estimate is $-0.19 per share (range $-0.19 – $-0.19) across 1 analysts. Full-year EPS is projected at $-0.54, rising to $-0.66 the following year.
How much revenue is Actuate Therapeutics, Inc. Common stock expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading ACTU lately?+
As of Nov 19, 2026, 2 of 2 active firms rate ACTU a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ACTU calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.